Neoadjuvant endocrine treatment in breast cancer: Analysis of daily practice in large cancer center to facilitate decision making

American Journal of Surgery

Volumn 208, Issue 5, 2014, Pages 756-763

  Debled, Marc ^a   Auxepaules, Gaël ^a   De Lara, Christine Tunon ^a   Garbay, Delphine ^a   Brouste, Véronique ^a   Bussières, Emmanuel ^a   Mauriac, Louis ^a   Macgrogan, Gaëtan ^a  

^a INSTITUT BERGONIÉ   (France)

Author keywords

Breast neoplasms; Breast conserving surgery; Neoadjuvant endocrine therapy; Shared decision making

Indexed keywords

AROMATASE INHIBITOR; ESTROGEN RECEPTOR; MEGESTROL ACETATE; PROGESTERONE RECEPTOR; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CENTER; CANCER GRADING; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CLINICAL PRACTICE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PATIENT DECISION MAKING; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR VOLUME; ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; BREAST NEOPLASMS; DECISION MAKING; EVALUATION STUDY; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PATIENT PARTICIPATION; SEGMENTAL MASTECTOMY; STATISTICS AND NUMERICAL DATA; SURVIVAL; TUMOR RECURRENCE; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DECISION MAKING; FEMALE; HUMANS; MASTECTOMY, SEGMENTAL; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PATIENT PARTICIPATION; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TAMOXIFEN; TREATMENT OUTCOME;

EID: 84911373444     PISSN: 00029610     EISSN: 18791883     Source Type: Journal    
DOI: 10.1016/j.amjsurg.2013.12.032     Document Type: Article

References (22)

1. J. Mathew, K.S. Asgeirsson, and L.R. Jackson Neoadjuvant endocrine treatment in primary breast cancer - review of literature Breast 18 2009 339 344
2. D. Mauri, N. Pavlidis, and J.P. Ioannidis Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-Analysis J Natl Cancer Inst 97 2005 188 194
3. D.A. Cameron, W. Jack, and P. Forouhi Oestrogen receptor directed primary systemic therapy: a randomised trial compared with conventional therapy in operable breast cancer Breast Cancer Res Treat 76 Suppl 2002 S52 Abstract 157
4. J.C. Gazet, H.T. Ford, and R. Gray Estrogen-receptor-directed neoadjuvant therapy for breast cancer: results of a randomised trial using formestane and methotrexate, mitozantrone and mitomycin C (MMM) chemotherapy Ann Oncol 12 2001 685 691
5. V.F. Semiglazov, V.V. Semiglazov, and G.A. Dashyan Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer Cancer 110 2007 244 254
6. A. Goldhirsch, W.C. Wood, and A.S. Coates Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 Ann Oncol 22 2011 1736 1747
7. L. Mauriac, M. Debled, and M. Durand Neoadjuvant tamoxifen for hormone-sensitive non-metastatic breast carcinomas in early postmenopausal women Ann Oncol 13 2002 293 298
8. C.W. Elston, and I.O. Ellis Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up Histopathology 41 2002 154 161
9. E. Mehrara, E. Forssell-Aronsson, and H. Ahlman Specific growth rate versus doubling time for quantitative characterization of tumor growth rate Cancer Res 67 2007 3970 3975
10. M. Clarke, R. Collins, and S. Darby Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials Lancet 366 2005 2087 2106
11. J.M. Dixon, J. Jackson, and L. Renshaw Neoadjuvant tamoxifen and aromatase inhibitors: comparisons and clinical outcomes J Steroid Biochem Mol Biol 86 2003 295 299
12. L. Cataliotti, A.U. Buzdar, and S. Noguchi Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) trial Cancer 106 2006 2095 2103
13. W. Eiermann, S. Paepke, and J. Appfelstaedt Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study Ann Oncol 12 2001 1527 1532
14. I.E. Smith, M. Dowsett, and S.R. Ebbs Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial J Clin Oncol 23 2005 5108 5116
15. J. Dixon, and E.J. Macaskill Neoadjuvant Endocrine Therapy 2009 American Society of Clinical Oncology Alexandria, VA 39 43
16. U.E. Krainick-Strobel, W. Lichtenegger, and D. Wallwiener Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer: a phase IIb/III trial to investigate optimal duration of preoperative endocrine therapy BMC Cancer 8 2008 62
17. I. Soubeyran, N. Quenel, and J.M. Coindre pS2 protein: a marker improving prediction of response to neoadjuvant tamoxifen in post-menopausal breast cancer patients Br J Cancer 74 1996 1120 1125
18. A. Makris, T.J. Powles, and S.E. Ashley A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer Ann Oncol 9 1998 1179 1184
19. J.S. Thomas, H.S. Julian, and R.V. Green Histopathology of breast carcinoma following neoadjuvant systemic therapy: a common association between letrozole therapy and central scarring Histopathology 51 2007 219 226
20. M.J. Ellis, Y. Tao, and J. Luo Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics J Natl Cancer Inst 100 2008 1380 1388
21. M.J. Ellis, W.R. Miller, and Y. Tao Aromatase expression and outcomes in the P024 neoadjuvant endocrine therapy trial Breast Cancer Res Treat 116 2009 371 378
22. M. Dowsett, I.E. Smith, and S.R. Ebbs Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer J Natl Cancer Inst 99 2007 167 170